Lecander I, Astedt B
Br J Haematol. 1986 Feb;62(2):221-8. doi: 10.1111/j.1365-2141.1986.tb02925.x.
A specific plasminogen activator inhibitor was isolated from the plasma of pregnant women by matrix-bound, cross reacting monoclonal antibodies against placental plasminogen activator inhibitor. The pregnancy plasma plasminogen activator inhibitor (PP-PA-I) was found to be immunologically different from the inhibitor produced by endothelial cells. Its molecular weight was 70 000 daltons. It formed complexes with urokinase (u-PA) and with plasminogen activator of the tissue type (t-PA), similar to those formed by the placental plasminogen activator inhibitor (PI-PA-I). It did not inhibit plasmin. For measuring PP-PA-I, an enzyme-linked immunosorbent assay (ELISA) was designed using monoclonal and polyclonal antibodies against the placental inhibitor. Concentrations of PP-PA-I increased successively during pregnancy, and fell sharply after delivery. This inhibitor could not be detected in normal non-pregnancy plasma. The results indicate that the inhibitor isolated from pregnancy plasma is responsible for the depressed fibrinolytic activity during pregnancy, and that the placenta is the source of the inhibitor.
通过针对胎盘纤溶酶原激活物抑制剂的基质结合交叉反应单克隆抗体，从孕妇血浆中分离出一种特异性纤溶酶原激活物抑制剂。发现妊娠血浆纤溶酶原激活物抑制剂（PP-PA-I）在免疫上与内皮细胞产生的抑制剂不同。其分子量为70000道尔顿。它与尿激酶（u-PA）和组织型纤溶酶原激活物（t-PA）形成复合物，类似于胎盘纤溶酶原激活物抑制剂（PI-PA-I）形成的复合物。它不抑制纤溶酶。为了测定PP-PA-I，使用针对胎盘抑制剂的单克隆和多克隆抗体设计了一种酶联免疫吸附测定法（ELISA）。PP-PA-I的浓度在孕期依次升高，分娩后急剧下降。在正常非妊娠血浆中检测不到这种抑制剂。结果表明，从妊娠血浆中分离出的抑制剂是孕期纤溶活性降低的原因，且胎盘是该抑制剂的来源。
